Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Future Hospital Journal|May 18, 2019
The millennial doctor - A blue collar worker?Orod Osanlou, Richard Hull
Advances in Pharmacology (San Diego, Calif.)|May 27, 2018
Pharmacogenetics of Adverse Drug ReactionsOrod Osanlou, Munir Pirmohamed, Ann K Daly
British Journal of Clinical Pharmacology|July 7, 2015
Social media and pharmacovigilance: A review of the opportunities and challengesRichard Sloane, Orod Osanlou, David Lewis, et al.
Clinical Infection in Practice|December 31, 2019
Adenovirus Type 7 causing severe lower respiratory tract infection in immunocompetent adults: a comparison of two contrasting cases from an intensive care unit in North West EnglandTom Wingfield, Luke Dearden, Pete Calvert, et al.
Clinical Pharmacology and Therapeutics|March 18, 2026
Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID-19: A Dose-Escalating, Randomized Controlled Phase Ib StudyTim Rowland, Richard FitzGerald, Elizabeth Challenger, et al.
Epidemiology and Infection|January 22, 2024
The predictive role of symptoms in COVID-19 diagnostic models: A longitudinal insightOlivia Bird, Eva P Galiza, David Neil Baxter, et al.
The New England Journal of Medicine|June 30, 2021
Safety and Efficacy of NVX-CoV2373 Covid-19 VaccinePaul T Heath, Eva P Galiza, David N Baxter, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 9, 2022
Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled TrialPaul T Heath, Eva P Galiza, David Neil Baxter, et al.
Lancet (London, England)|December 5, 2021
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trialAlasdair P S Munro, Leila Janani, Victoria Cornelius, et al.
The Journal of Infection|August 9, 2025
Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trialLeila Janani, Alasdair P S Munro, Annie Wright, et al.
Pageof 2